دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Flashback Foreword: Afatinib for the Treatment of Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer.
Stinchcombe, Thomas E. MD 1,2,
doi : 10.1200/JCO.22.02848
Volume 41(16) pgs. 2867-3077 June 1, 2023
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations.
Sequist, Lecia V.; Yang, James Chih-Hsin; Yamamoto, Nobuyuki; O'Byrne, Kenneth; Hirsh, Vera; Mok, Tony; Geater, Sarayut Lucien; Orlov, Sergey; Tsai, Chun-Ming; Boyer, Michael; Su, Wu-Chou; Bennouna, Jaafar; Kato, Terufumi; Gorbunova, Vera; Lee, Ki Hyeong; Shah, Riyaz; Massey, Dan; Zazulina, Victoria; Shahidi, Mehdi; Schuler, Martin
doi : 10.1200/JCO.22.02547
The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations.
Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer?.
Tendler, Salomon MD, PhD 1; Rudin, Charles M. MD, PhD 1,,
doi : 10.1200/JCO.23.00148
Fine Tuning Venous Thromboembolism Risk Prediction in Patients With Cancer.
Connors, Jean M. MD 1,,
doi : 10.1200/JCO.23.00100
Intensive Caring: Reminding Patients They Matter.
Chochinov, Harvey Max MD, PhD 1,,
doi : 10.1200/JCO.23.00042
Precision Palliative Care as a Pragmatic Solution for a Care Delivery Problem.
Sedhom, Ramy MD 1,2,3; Shulman, Lawrence N. MD 1,3,; Parikh, Ravi B. MD, MPP 1,2,3,,
doi : 10.1200/JCO.22.02532
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Paz-Ares, Luis MD, PhD 1,; Champiat, Stephane MD, PhD 2,; Lai, W. Victoria MD 3,; Izumi, Hiroki MD, PhD 4,; Govindan, Ramaswamy MD 5,; Boyer, Michael MB, BS, PhD 6,; Hummel, Horst-Dieter MD 7,; Borghaei, Hossein DO 8,; Johnson, Melissa L. MD 9,; Steeghs, Neeltje MD, PhD 10,; Blackhall, Fiona MD, PhD 11,; Dowlati, Afshin MD 12,; Reguart, Noemi MD, PhD 13,; Yoshida, Tatsuya MD, PhD 14,; He, Kai MD, PhD 15,; Gadgeel, Shirish M. MD 16,; Felip, Enriqueta MD, PhD 17,; Zhang, Yiran PhD 18,; Pati, Amrita PhD 18,; Minocha, Mukul PhD 18,; Mukherjee, Sujoy MD 18,; Goldrick, Amanda MD 18,; Nagorsen, Dirk MD, PhD 18,; Hashemi Sadraei, Nooshin MD 18,; Owonikoko, Taofeek K. MD, PhD 19,
doi : 10.1200/JCO.22.02823
Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatments. Delta-like ligand 3 (DLL3) is aberrantly expressed in most SCLC.
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.
Makker, Vicky MD 1,; Colombo, Nicoletta MD 2,; Herraez, Antonio Casado MD 3; Monk, Bradley J. MD 4; Mackay, Helen MD 5,; Santin, Alessandro D. MD 6; Miller, David S. MD 7; Moore, Richard G. MD 8; Baron-Hay, Sally MBBS 9,; Ray-Coquard, Isabelle MD 10,; Ushijima, Kimio MD 11; Yonemori, Kan MD 12,; Kim, Yong Man MD 13; Guerra Alia, Eva M. MD 14; Sanli, Ulus A. MD 15; Bird, Steven MS 16,; Orlowski, Robert MD 16,; McKenzie, Jodi PhD 17,; Okpara, Chinyere PhD 18,; Barresi, Gianmaria MD 19,; Lorusso, Domenica MD 20,
doi : 10.1200/JCO.22.02152
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts.
Munoz, Andres MD, PhD 1,2,; Ay, Cihan MD, PhD 3,4; Grilz, Ella MD, PhD 3; Lopez, Sonia BSc, PhD 5; Font, Carme MD, PhD 2,6; Pachon, Vanesa MD 2,7; Castellon, Victoria MD, PhD 2,8; Martinez-Marin, Virginia MD, PhD 2,9; Salgado, Mercedes MD 2,10,; Martinez, Eva MD 2,11; Calzas, Julia MD 2,12; Ortega, Laura MD 1,2,; Ruperez, Ana MD 2,13,; Salas, Eduardo MD, PhD 14,; Pabinger, Ingrid MD, PhD 3; Soria, Jose Manuel BSc, PhD 5,
doi : 10.1200/JCO.22.00255
Venous thromboembolism (VTE) is a leading cause of death among patients with cancer. The Khorana score was developed for assessing the risk of VTE in outpatients with cancer receiving chemotherapy, but its accuracy in identifying patients at high risk has been questioned.
Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems.
Li, Ang MD, MS 1,; La, Jennifer PhD 2; May, Sarah B. MS 3; Guffey, Danielle MS 3; da Costa, Wilson L. Jr PhD 4; Amos, Christopher I. PhD 3,4; Bandyo, Raka MS 5; Milner, Emily M. BS 6; Kurian, Karen M. BS 6; Chen, Daniel C.R. MD 2,7; Do, Nhan V. MD 2,7; Granada, Carolina BS 1; Riaz, Nimrah MS 1; Brophy, Mary T. MD 2,8; Chitalia, Vipul MD 2,9,10; Gaziano, J. Michael MD 2,11,12; Garcia, David A. MD 13,; Carrier, Marc MD, MSc 14,; Flowers, Christopher R. MD, MS 15,; Zakai, Neil A. MD, MSc 16; Fillmore, Nathanael R. PhD 2,8,11,17
doi : 10.1200/JCO.22.01542
Venous thromboembolism (VTE), especially pulmonary embolism (PE) and lower extremity deep vein thrombosis (LE-DVT), is a serious and potentially preventable complication for patients with cancer undergoing systemic therapy.
Working, Low Income, and Cancer Caregiving: Financial and Mental Health Impacts.
Bradley, Cathy J. PhD, MPA 1,; Kitchen, Sara MPH 2; Owsley, Kelsey M. PhD, MPH 3
doi : 10.1200/JCO.22.02537
Approximately 6 million people provide caregiving to people diagnosed with cancer. Many must remain employed to support their household and to have access to health insurance. It is unknown if caregiving for a spouse diagnosed with cancer is associated with greater financial and mental stress relative to providing care for a spouse with different conditions.
Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia.
Farrar, Jason E. MD 1,,; Smith, Jenny L. MS 2; Othus, Megan PhD 3,; Huang, Benjamin J. MD 4; Wang, Yi-Cheng MS 5; Ries, Rhonda MA 2; Hylkema, Tiffany BS 2,; Pogosova-Agadjanyan, Era L. BS, BA 2; Challa, Sneha MS 2,; Leonti, Amanda MS 2; Shaw, Timothy I. PhD 6,; Triche, Timothy J. Jr PhD 7,; Gamis, Alan S. MD, MPH 8,; Aplenc, Richard MD, PhD, MSCE 9,; Kolb, E. Anders MD 10,; Ma, Xiaotu PhD 11; Stirewalt, Derek L. MD 2,; Alonzo, Todd A. PhD 5,12; Meshinchi, Soheil MD, PhD 2,13
doi : 10.1200/JCO.22.01114
Optimized strategies for risk classification are essential to tailor therapy for patients with biologically distinctive disease. Risk classification in pediatric acute myeloid leukemia (pAML) relies on detection of translocations and gene mutations.
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Munster Study Group.
van Weelderen, Romy E. MD 1,2,; Klein, Kim MD, PhD 1,2,3; Harrison, Christine J. PhD 4; Jiang, Yilin MSc 1; Abrahamsson, Jonas MD, PhD 5; Arad-Cohen, Nira MD, PhD 6; Bart-Delabesse, Emmanuelle PharmD, PhD 7; Buldini, Barbara MD, PhD 8,; De Moerloose, Barbara MD, PhD 9,; Dworzak, Michael N. MD, PhD 10; Elitzur, Sarah MD 11,; Fernandez Navarro, Jose M. MD 12; Gerbing, Robert B. MA 13; Goemans, Bianca F. MD, PhD 1; de Groot-Kruseman, Hester A. PhD 1,14; Guest, Erin MD 15,; Ha, Shau-Yin MD, PhD 16; Hasle, Henrik MD, PhD 17,; Kelaidi, Charikleia MD 18; Lapillonne, Helene MD, PhD 19; Leverger, Guy MD 19; Locatelli, Franco MD, PhD 20,; Masetti, Riccardo MD 21; Miyamura, Takako MD, PhD 22,; Noren-Nystrom, Ulrika MD, PhD 23; Polychronopoulou, Sophia MD, PhD 18; Rasche, Mareike MD 24; Rubnitz, Jeffrey E. MD, PhD 25,; Stary, Jan MD, PhD 26; Tierens, Anne MD, PhD 27,; Tomizawa, Daisuke MD, PhD 28,; Zwaan, C. Michel MD, PhD 1,29,; Kaspers, Gertjan J.L. MD, PhD 1,2
doi : 10.1200/JCO.22.02120
A previous study by the International Berlin-Frankfurt-Munster Study Group (I-BFM-SG) on childhood KMT2A-rearranged (KMT2A-r) AML demonstrated the prognostic value of the fusion partner.
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212).
Stahler, Arndt MD 1,; Hoppe, Beeke CandMed 1; Na, Il-Kang MD 1,2,3,4,; Keilholz, Luisa BSc 1; Muller, Lothar MD 5,; Karthaus, Meinolf MD 6,; Fruehauf, Stefan MD 7; Graeven, Ullrich MD 8,; Fischer von Weikersthal, Ludwig MD 9,; Goekkurt, Eray MD 10,11,; Kasper, Stefan MD 2,12,; Kind, Andreas Jay CandMed 1,; Kurreck, Annika MD 1,; Alig, Annabel Helga Sophie MD 1,; Held, Swantje MSc 13; Reinacher-Schick, Anke MD 14,; Heinemann, Volker MD 2,15,; Horst, David MD 2,16; Jarosch, Armin MD 16; Stintzing, Sebastian MD 1,2,; Trarbach, Tanja MD 12,17; Modest, Dominik Paul MD 1,2,
doi : 10.1200/JCO.22.02582
Consensus molecular subtypes (CMSs) were evaluated as prognostic and predictive biomarkers of patients with RAS wild-type metastatic colorectal cancer (mCRC) receiving fluorouracil and folinic acid (FU/FA) with or without panitumumab (Pmab) after Pmab + mFOLFOX6 induction within the randomized phase II PanaMa trial.
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
Squifflet, Pierre MSc 1,; Saad, Everardo D. MD 1,; Loibl, Sibylle MD 2,; van Mackelenbergh, Marion T. MD 2,; Untch, Michael MD 3,; Rastogi, Priya MD 4,; Gianni, Luca MD 5,; Schneeweiss, Andreas MD 6,; Conte, Pierfranco MD 7,; Piccart, Martine MD 8,; Bonnefoi, Herve MD 9,; Jackisch, Christian MD 10,; Nekljudova, Valentina PhD 1,; Tang, Gong PhD 11; Valagussa, Pinuccia MD 12; Neate, Colin MD 13,; Gelber, Richard PhD 14,; Poncet, Coralie PhD 15; Heinzmann, Dominik MD 16,; Denkert, Carsten MD 17,; Geyer, Charles E. Jr MD 18,; Cortes, Javier MD 19,; Guarneri, Valentina MD 7,; de Azambuja, Evandro MD 8,; Cameron, David MD 20,; Ismael, Gustavo MD 21; Wolmark, Norman MD 18,; Cortazar, Patricia MD 22,; Buyse, Marc ScD 1,23,; on behalf of the CTNeoBC Project
doi : 10.1200/JCO.22.02363
Pathologic complete response (pCR) has prognostic importance and is frequently used as a primary end point, but doubts remain about its validity as a surrogate for event-free survival (EFS) and overall survival (OS) in human epidermal growth factor receptor 2 (HER2)-positive, early breast cancer.
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
van Mackelenbergh, Marion T. MD, PhD 1,; Loibl, Sibylle MD 2; Untch, Michael MD 3; Buyse, Marc PhD 4; Geyer, Charles E. Jr MD 5; Gianni, Luca MD 6; Schneeweiss, Andreas MD, PhD 7; Conte, Pierfranco MD 8; Piccart, Martine MD 9; Bonnefoi, Herve MD 10; Jackisch, Christian MD 11; Nekljudova, Valentina PhD 2; Tang, Gong MD 12; Valagussa, Pinuccia MD 13; Neate, Colin PhD 14; Gelber, Richard MD 15; Poncet, Coralie MD 16; Squifflet, Pierre PhD 4; Saad, Everardo D. PhD 4; Heinzmann, Dominik PhD 17; Denkert, Carsten MD, PhD 18; Rastogi, Priya MD 5; Cortes, Javier MD 19; Guarneri, Valentina MD 8; de Azambuja, Evandro MD 9; Cameron, David MD 20; Ismael, Gustavo MD 21; Wolmark, Norman MD 5; Cortazar, Patricia PhD 22; on behalf of the CTNeoBC project
doi : 10.1200/JCO.22.02241
The achievement of pathologic complete response (pCR) is strongly prognostic for event-free survival (EFS) and overall survival (OS) in patients with early breast cancer (EBC), and adapting postneoadjuvant therapy improves long-term outcomes for patients with HER2-positive disease not achieving pCR.
Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy.
Daneshmand, Siamak MD 1,,; Cary, Clint MD 2; Masterson, Timothy MD 2; Einhorn, Lawrence MD 3,; Adra, Nabil MD 3,; Boorjian, Stephen A. MD 4,; Kollmannsberger, Christian MD 5; Schuckman, Anne MD 1,; So, Alan MD 6,; Black, Peter MD 6,; Bagrodia, Aditya MD 7; Skinner, Eila MD 8,; Alemozaffar, Mehrdad MD 9; Brand, Timothy MD 10,; Eggener, Scott MD 11,; Pierorazio, Phillip MD 12; Stratton, Kelly MD 13,; Nappi, Lucia MD 5,; Nichols, Craig MD 14; Luo, Chunqiao MS 15,; Li, Ming PhD 15; Hu, Brian MD 16,
doi : 10.1200/JCO.22.00624
The long-term toxicities of chemotherapy and radiotherapy can represent a significant burden to testicular cancer survivors. Retroperitoneal lymph node dissection (RPLND) is an established treatment for testicular germ cell tumors with minimal late morbidity although little data exist on its efficacy in early metastatic seminoma
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
Burgos, Leire PhD 1; Tamariz-Amador, Luis-Esteban MD 1; Puig, Noemi MD, PhD 2,; Cedena, Maria-Teresa MD 3,; Guerrero, Camila MSc 1; Jelinek, Tomas MD, PhD 4,; Johnson, Sarah PhD 5; Milani, Paolo MD 6,; Cordon, Lourdes PhD 7,; Perez, Jose J. PhD 2; Lasa, Marta PhD 1; Termini, Rosalinda MSc 1; Oriol, Albert MD 8,; Hernandez, Miguel-Teodoro MD, PhD 9,; Palomera, Luis MD 10,; Martinez-Martinez, Rafael MD 11; de la Rubia, Javier MD 12,; de Arriba, Felipe MD 13,; Rios, Rafael MD, PhD 14,; Gonzalez, Maria-Esther MD 15; Gironella, Mercedes MD 16,; Cabanas, Valentin MD 17,; Casanova, Maria MD 18; Krsnik, Isabel MD 14,; Perez-Montana, Albert MD, PhD 19,; Gonzalez-Calle, Veronica MD, PhD 2,; Rodriguez-Otero, Paula MD, PhD 1,; Maisnar, Vladimir MD 20; Hajek, Roman MD, PhD 4,; Van Rhee, Fritz MD 5,; Jimenez-Zepeda, Victor MD 21,; Palladini, Giovanni MD, PhD 6,; Merlini, Giampaolo MD, PhD 6; Orfao, Alberto MD, PhD 22,; de la Cruz, Javier PhD 3; Martinez-Lopez, Joaquin MD, PhD 3,; Lahuerta, Juan-Jose MD, PhD 3,; Rosinol, Laura MD, PhD 23,; Blade, Joan MD, PhD 23,; Mateos, Maria-Victoria MD, PhD 2,; San-Miguel, Jesus F. MD, PhD 1,; Paiva, Bruno PhD 1,; on behalf of the PETHEMA/GEM Cooperative Group
doi : 10.1200/JCO.22.01916
The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present with a monoclonal gammopathy of undetermined significance (MGUS)-like phenotype has been hypothesized, but methods to identify this subgroup are not standardized and its clinical significance is not properly validated.
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study.
Huang, Huiqiang MD 1,; Tao, Rong MD 2; Hao, Siguo MD 2; Yang, Yu MD 3; Cen, Hong MD 4; Zhou, Hui MD 5; Guo, Ye MD 6,; Zou, Liqun MD 7; Cao, Junning MM 8; Huang, Yunhong MD 9; Jin, Jie MD 10; Zhang, Liling MD 11; Yang, Haiyan MD 12; Xing, Xiaojing MD 13; Zhang, Huilai MD 14; Liu, Yanyan MD 15; Ding, Kaiyang MD 16; Qi, Qinzhou PhD 17,; Zhu, Xiaoli MM 17,; Zhu, Dan MM 17,; Wang, Siyuan MS 17,; Fang, Teng PhD 17,; Dai, Hangjun MS 17,; Shi, Qingmei MD, PhD 17,; Yang, Jason MD, PhD 17,
doi : 10.1200/JCO.22.02367
Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) is a rare and aggressive type of non-Hodgkin lymphoma with limited treatment options.
Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial).
Olofsson Bagge, Roger MD, PhD 1,2,3,; Nelson, Axel MD, PhD 4; Shafazand, Amir MD 3,5,; All-Eriksson, Charlotta MD, PhD 6; Cahlin, Christian MD, PhD 7,; Elander, Nils MD, PhD 8,; Helgadottir, Hildur MD, PhD 9,; Kiilgaard, Jens Folke MD, PhD 10; Kinhult, Sara MD, PhD 11; Ljuslinder, Ingrid MD, PhD 12; Mattsson, Jan MD, PhD 2; Rizell, Magnus MD, PhD 7; Sternby Eilard, Malin MD, PhD 7,; Ullenhag, Gustav J. MD, PhD 13,14,; Nilsson, Jonas A. PhD 1,15,; Ny, Lars MD, PhD 4,; Lindner, Per MD, PhD 7
doi : 10.1200/JCO.22.01705
About half of patients with metastatic uveal melanoma present with isolated liver metastasis, in whom the median survival is 6-12 months.
Financial Toxicity in Cancer Care: Implications for Clinical Care and Potential Practice Solutions.
Khan, Hiba M. MD, MPH 1; Ramsey, Scott MD, PhD 1,; Shankaran, Veena MD, MS 1,2,,
doi : 10.1200/JCO.22.01799
with cancer face an array of financial consequences as a result of their diagnosis and treatment, collectively referred to as financial toxicity (FT). In the past 10 years, the body of literature on this subject has grown tremendously, with a recent focus on interventions and mitigation strategies.
Long Noncoding RNA Signatures as Cancer Biomarkers.
Mas, Aina M. PhD 1,2; Huarte, Maite PhD 1,2,
doi : 10.1200/JCO.23.00381
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update.
Key, Nigel S. MBChB 1,,; Khorana, Alok A. MD 2,; Kuderer, Nicole M. MD 3,; Bohlke, Kari ScD 4; Lee, Agnes Y.Y. MD, MSc 5,; Arcelus, Juan I. MD, PhD 6,; Wong, Sandra L. MD, MS 7; Balaban, Edward P. DO 8; Flowers, Christopher R. MD, MS 9,; Gates, Leigh E. BA, CPHQ 10; Kakkar, Ajay K. MD, PhD 11,; Tempero, Margaret A. MD 12,; Gupta, Shilpi MD 13; Lyman, Gary H. MD, MPH 14,; Falanga, Anna MD 15,
doi : 10.1200/JCO.23.00294
To conduct an update of the ASCO venous thromboembolism (VTE) guideline. METHODS: After publication of potentially practice-changing clinical trials, identified through ASCO's signals approach to updating, an updated systematic review was performed for two guideline questions: perioperative thromboprophylaxis and treatment of VTE.
At a Loss: Patient Deaths and Clinical Research Coordinators.
Deary, Emma C. BA 1; Daskalakis, Elizabeth BA 1; Abrahm, Janet L. MD 2,3,; Morris, Sue E. PsyD 1,2,3,; Amonoo, Hermioni L. MD, MPP 1,2,3,
doi : 10.1200/JCO.23.00040
Determining the Efficacy of Pembrolizumab in Patients With Previously Treated Advanced Hepatocellular Carcinoma.
Lin, Timothy A. MD, MBA; Das, Ananya; McCaw, Zachary PhD; Ludmir, Ethan B. MD
doi : 10.1200/JCO.23.00072
A Brand New BRCA-CRisk Model Precisely Predicts the Prognosis of Patients With Breast Cancer and BRCA1/2 Mutation.
Zhao, Yu-Fei MD; Du, Jun-Xian MD; Zhu, Wei MD, PhD
doi : 10.1200/JCO.22.02893
